Piramal Pharma Targets Over $2 Billion in Global Pharma and Health by 2030

Piramal Pharma, chaired by Nandini Piramal, aims to become a global pharma and wellness giant exceeding $2 billion by FY30. They target significant growth across their CDMO, critical care, and consumer healthcare divisions. The company focuses on integrated services, cross-selling, and reinforcing global market presence with innovative brands.

Piramal Pharma is setting ambitious targets to become a global pharma and wellness giant, exceeding USD 2 billion by FY30, as stated by Chairperson Nandini Piramal on Wednesday.

The company's strategy includes growing its Contract Development and Manufacturing Organisation (CDMO) to a USD 1.2 billion entity within five years. Piramal shared that they plan to double CDMO revenues, expanding at twice the market rate of 6-7 percent, driven by integrated services, cross-selling, and unique offerings.

Additionally, the critical care vertical aims to reach USD 600 million, while the consumer healthcare division targets USD 200 million by FY30. The firm will focus on core power brands, enhancing media investment, channel expansion, and introducing pioneering products to drive growth across various markets.

(With inputs from agencies.)